Trials / Completed
CompletedNCT05427617
Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer
Clinical Application of Circulating Tumor DNA (ctDNA) to Guided the Late-Line Treatment for Patients With Late-Stage Breast Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 223 (actual)
- Sponsor
- Hunan Cancer Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a retrospective, observational, multi-center clinical study of circulating tumor DNA (ctDNA) to guide late-line therapy in late-stage metastatic breast cancer patients.
Detailed description
This study aims to evaluate the feasibility of plasma ctDNA mutation in guiding late-line treatment for late-stage metastatic breast cancer patients. Meanwhile, this study tries to evaluate the curative effect of ctDNA subtype-guided late-line therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Control group | Physician chosen treatment |
| DRUG | Case group | Druggable ctDNA alterations-guided therapy |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2019-06-30
- Completion
- 2021-06-30
- First posted
- 2022-06-22
- Last updated
- 2022-06-22
Source: ClinicalTrials.gov record NCT05427617. Inclusion in this directory is not an endorsement.